1065 related articles for article (PubMed ID: 15888152)
1. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
[TBL] [Abstract][Full Text] [Related]
2. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
[TBL] [Abstract][Full Text] [Related]
3. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
Feldman SR; Gottlieb AB; Bala M; Wu Y; Eisenberg D; Guzzo C; Li S; Dooley LT; Menter A
Br J Dermatol; 2008 Sep; 159(3):704-10. PubMed ID: 18627375
[TBL] [Abstract][Full Text] [Related]
4. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
Gottlieb AB; Evans R; Li S; Dooley LT; Guzzo CA; Baker D; Bala M; Marano CW; Menter A
J Am Acad Dermatol; 2004 Oct; 51(4):534-42. PubMed ID: 15389187
[TBL] [Abstract][Full Text] [Related]
5. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
Torii H; Nakagawa H;
J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
[TBL] [Abstract][Full Text] [Related]
6. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
7. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
Reich K; Nestle FO; Wu Y; Bala M; Eisenberg D; Guzzo C; Li S; Dooley LT; Griffiths CE
Eur J Dermatol; 2007; 17(5):381-6. PubMed ID: 17673380
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
[TBL] [Abstract][Full Text] [Related]
9. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
Tsai TF; Song M; Shen YK; Schenkel B; Choe YB; Kim NI; Lee JH; Lee JH; Song HJ; Youn JI;
J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
[TBL] [Abstract][Full Text] [Related]
11. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
[TBL] [Abstract][Full Text] [Related]
12. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
[TBL] [Abstract][Full Text] [Related]
13. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
[TBL] [Abstract][Full Text] [Related]
14. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
Reich K; Segaert S; Van de Kerkhof P; Durian C; Boussuge MP; Paolozzi L; Wajdula J; Boggs R
Dermatology; 2009; 219(3):239-49. PubMed ID: 19752505
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.
Salim A; Tan E; Ilchyshyn A; Berth-Jones J
Br J Dermatol; 2006 Jun; 154(6):1169-74. PubMed ID: 16704650
[TBL] [Abstract][Full Text] [Related]
16. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
Lebwohl M; Papp K; Han C; Schenkel B; Yeilding N; Wang Y; Krueger GG
Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
[TBL] [Abstract][Full Text] [Related]
18. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
[TBL] [Abstract][Full Text] [Related]
19. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
[TBL] [Abstract][Full Text] [Related]
20. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
Antoni C; Krueger GG; de Vlam K; Birbara C; Beutler A; Guzzo C; Zhou B; Dooley LT; Kavanaugh A;
Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]